Eric Verdin on Muck Rack

Eric Verdin

As seen in: We're not getting any younger... yet., National Institutes of Health, Nature, ScienceDirect, Taylor & Francis Online, Science Magazine, Cell Metabolism, Cell Press, Journal of Virology, Training to Age Better Podcast, Marin Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Eric

Contact Eric, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Advancing longevity clinics - an international roundtable

|
By Joanna Bensz, Eric Verdin, David Karow, Andrea B. Maier
| Taylor & Francis Online
Introduction This paper is based on the presentations and panel discussions from the 2024 Roundtable, and builds on the white paper published from the 2023 meeting, but with greater focus on best practices and guidelines for optimizing the client journey and improving care delivery, diagnostics, and intervention tools. The 2023 white paper, In Search of Best Practices for Longevity Clinics [Citation1], served as one of the important documents for the industry.
Open in Who Shared Issue with article?

Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial - Nature Aging

|
By Dominic Denk, Davide D’Amico, Christoph Steup, Ryan W. Kwok, Rafael J. Argüello, Eric Verdin, Lucía Alcober-Boquet
| Nature Verified
Abstract Mitochondrial dysfunction and stem cell exhaustion contribute to age-related immune decline, yet clinical interventions targeting immune aging are lacking. Recently, we demonstrated that urolithin A (UA), a mitophagy inducer, expands T memory stem cells (TSCM) and naive T cells in mice. In this randomized, double-blind, placebo-controlled trial, 50 healthy middle-aged adults received oral UA (1,000 mg day−1) or placebo for 4 weeks; time points of analysis were baseline and day 28.
Open in Who Shared Issue with article?

Emerging strategies, applications and challenges of targeting NAD+ in the clinic - Nature Aging

|
By Jianying Zhang, Sofie Lautrup, Hilde Loge Nilsen, Jonas T. Treebak, Leiv Otto Watne, Geir Selbæk, Lindsay Wu, Torbjørn Omland, Eija Pirinen, Mathias Ziegler, Ole-Bjørn Tysnes, Rubén Zapata-Pérez, Santina Bruzzone, Michela Deleidi, Georges E. Janssens, Riekelt Houtkooper, Morten Scheibye-Knudsen, Masaya Koshizaka, Koutaro Yokote, Eric Verdin, Vilhelm A. Bohr, Charalampos Tzoulis, He-Ling Wang, David Sinclair
| Nature Verified
Abstract Beyond their classical functions as redox cofactors, recent fundamental and clinical research has expanded our understanding of the diverse roles of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) in signaling pathways, epigenetic regulation and energy homeostasis. Moreover, NAD and NADP influence numerous diseases as well as the processes of aging, and are emerging as targets for clinical intervention.
Open in Who Shared Issue with article?
See all 26 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified